AlphaCentric Advisors LLC acquired a new position in shares of Danaher Co. (NYSE:DHR - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,175 shares of the conglomerate's stock, valued at approximately $958,000.
A number of other institutional investors and hedge funds also recently modified their holdings of DHR. Heck Capital Advisors LLC bought a new stake in Danaher in the fourth quarter valued at approximately $27,000. Decker Retirement Planning Inc. bought a new stake in Danaher in the 4th quarter valued at $31,000. Golden State Wealth Management LLC acquired a new stake in Danaher during the 4th quarter valued at $31,000. Strategic Financial Concepts LLC bought a new position in Danaher during the fourth quarter worth $31,000. Finally, Pineridge Advisors LLC increased its holdings in shares of Danaher by 63.3% in the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate's stock valued at $34,000 after purchasing an additional 57 shares during the last quarter. 79.05% of the stock is owned by institutional investors.
Danaher Price Performance
Shares of DHR stock traded down $0.50 on Wednesday, hitting $204.03. 2,987,025 shares of the company's stock were exchanged, compared to its average volume of 4,465,977. Danaher Co. has a 12 month low of $196.80 and a 12 month high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The company has a 50 day moving average of $228.34 and a 200 day moving average of $248.10. The stock has a market cap of $147.37 billion, a P/E ratio of 38.67, a price-to-earnings-growth ratio of 2.63 and a beta of 0.83.
Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the firm posted $2.09 EPS. On average, equities research analysts predict that Danaher Co. will post 7.67 EPS for the current year.
Danaher Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.53%. The ex-dividend date was Friday, December 27th. Danaher's dividend payout ratio (DPR) is 20.45%.
Insider Buying and Selling
In other news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company's stock, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.90% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
DHR has been the subject of several research analyst reports. TD Cowen lifted their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a "buy" rating in a report on Wednesday, October 23rd. Jefferies Financial Group decreased their target price on Danaher from $285.00 to $260.00 and set a "buy" rating on the stock in a research report on Wednesday, January 29th. Bank of America raised Danaher from a "neutral" rating to a "buy" rating and set a $290.00 price target for the company in a report on Friday, December 13th. Scotiabank initiated coverage on Danaher in a report on Monday, December 23rd. They issued a "sector perform" rating and a $265.00 price objective on the stock. Finally, Wolfe Research raised Danaher from a "peer perform" rating to an "outperform" rating and set a $285.00 target price for the company in a report on Thursday, October 31st. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $278.00.
Read Our Latest Report on DHR
Danaher Company Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
